174 related articles for article (PubMed ID: 16277711)
1. Steroid use in PROWESS severe sepsis patients treated with drotrecogin alfa (activated).
Levy H; Laterre PF; Bates B; Qualy RL
Crit Care; 2005 Oct; 9(5):R502-7. PubMed ID: 16277711
[TBL] [Abstract][Full Text] [Related]
2. Clinical effectiveness and cost-effectiveness of drotrecogin alfa (activated) (Xigris) for the treatment of severe sepsis in adults: a systematic review and economic evaluation.
Green C; Dinnes J; Takeda A; Shepherd J; Hartwell D; Cave C; Payne E; Cuthbertson BH
Health Technol Assess; 2005 Mar; 9(11):1-126, iii-iv. PubMed ID: 15774234
[TBL] [Abstract][Full Text] [Related]
3. Extended evaluation of recombinant human activated protein C United States Trial (ENHANCE US): a single-arm, phase 3B, multicenter study of drotrecogin alfa (activated) in severe sepsis.
Bernard GR; Margolis BD; Shanies HM; Ely EW; Wheeler AP; Levy H; Wong K; Wright TJ;
Chest; 2004 Jun; 125(6):2206-16. PubMed ID: 15189943
[TBL] [Abstract][Full Text] [Related]
4. Drotrecogin alfa (activated) administration across clinically important subgroups of patients with severe sepsis.
Ely EW; Laterre PF; Angus DC; Helterbrand JD; Levy H; Dhainaut JF; Vincent JL; Macias WL; Bernard GR;
Crit Care Med; 2003 Jan; 31(1):12-9. PubMed ID: 12544987
[TBL] [Abstract][Full Text] [Related]
5. Clinical impact of stress dose steroids in patients with septic shock: insights from the PROWESS-Shock trial.
Póvoa P; Salluh JI; Martinez ML; Guillamat-Prats R; Gallup D; Al-Khalidi HR; Thompson BT; Ranieri VM; Artigas A
Crit Care; 2015 Apr; 19(1):193. PubMed ID: 25928214
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of recombinant human activated protein C for severe sepsis.
Bernard GR; Vincent JL; Laterre PF; LaRosa SP; Dhainaut JF; Lopez-Rodriguez A; Steingrub JS; Garber GE; Helterbrand JD; Ely EW; Fisher CJ;
N Engl J Med; 2001 Mar; 344(10):699-709. PubMed ID: 11236773
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness and safety of drotrecogin alfa (activated) for severe sepsis: a meta-analysis and metaregression.
Kalil AC; LaRosa SP
Lancet Infect Dis; 2012 Sep; 12(9):678-86. PubMed ID: 22809883
[TBL] [Abstract][Full Text] [Related]
8. Drotrecogin alfa (activated) treatment in severe sepsis from the global open-label trial ENHANCE: further evidence for survival and safety and implications for early treatment.
Vincent JL; Bernard GR; Beale R; Doig C; Putensen C; Dhainaut JF; Artigas A; Fumagalli R; Macias W; Wright T; Wong K; Sundin DP; Turlo MA; Janes J
Crit Care Med; 2005 Oct; 33(10):2266-77. PubMed ID: 16215381
[TBL] [Abstract][Full Text] [Related]
9. Predictors of hospital mortality for patients with severe sepsis treated with Drotrecogin alfa (activated).
Micek ST; Isakow W; Shannon W; Kollef MH
Pharmacotherapy; 2005 Jan; 25(1):26-34. PubMed ID: 15767217
[TBL] [Abstract][Full Text] [Related]
10. Drotrecogin alfa: a second look. More clinical trials in severe sepsis: mostly negative results.
Prescrire Int; 2007 Feb; 16(87):7-9. PubMed ID: 17323514
[TBL] [Abstract][Full Text] [Related]
11. Effect of factor V Leiden polymorphism in severe sepsis and on treatment with recombinant human activated protein C.
Yan SB; Nelson DR
Crit Care Med; 2004 May; 32(5 Suppl):S239-46. PubMed ID: 15118525
[TBL] [Abstract][Full Text] [Related]
12. Benefit-risk assessment of drotrecogin alfa (activated) in the treatment of sepsis.
De Backer D
Drug Saf; 2007; 30(11):995-1010. PubMed ID: 17973539
[TBL] [Abstract][Full Text] [Related]
13. Safety, pharmacokinetics, and pharmacodynamics of drotrecogin alfa (activated) in children with severe sepsis.
Barton P; Kalil AC; Nadel S; Goldstein B; Okhuysen-Cawley R; Brilli RJ; Takano JS; Martin LD; Quint P; Yeh TS; Dalton HJ; Gessouron MR; Brown KE; Betts H; Levin M; Macias WL; Small DS; Wyss VL; Bates BM; Utterback BG; Giroir BP
Pediatrics; 2004 Jan; 113(1 Pt 1):7-17. PubMed ID: 14702440
[TBL] [Abstract][Full Text] [Related]
14. Influence of enrollment sequence effect on observed outcomes in the ADDRESS and PROWESS studies of drotrecogin alfa (activated) in patients with severe sepsis.
Laterre PF; Macias WL; Janes J; Williams MD; Nelson DR; Girbes AR; Dhainaut JF; Abraham E
Crit Care; 2008; 12(5):R117. PubMed ID: 18786266
[TBL] [Abstract][Full Text] [Related]
15. Drotrecogin alfa (recombinant human activated protein C) for the treatment of severe sepsis.
McCoy C; Matthews SJ
Clin Ther; 2003 Feb; 25(2):396-421. PubMed ID: 12749504
[TBL] [Abstract][Full Text] [Related]
16. The clinical evaluation committee in a large multicenter phase 3 trial of drotrecogin alfa (activated) in patients with severe sepsis (PROWESS): role, methodology, and results.
Dhainaut JF; Laterre PF; LaRosa SP; Levy H; Garber GE; Heiselman D; Kinasewitz GT; Light RB; Morris P; Schein R; Sollet JP; Bates BM; Utterback BG; Maki D
Crit Care Med; 2003 Sep; 31(9):2291-301. PubMed ID: 14501959
[TBL] [Abstract][Full Text] [Related]
17. An evaluation of the cost effectiveness of drotrecogin alfa (activated) relative to the number of organ system failures.
Betancourt M; McKinnon PS; Massanari RM; Kanji S; Bach D; Devlin JW
Pharmacoeconomics; 2003; 21(18):1331-40. PubMed ID: 14750900
[TBL] [Abstract][Full Text] [Related]
18. An updated meta-analysis to understand the variable efficacy of drotrecogin alfa (activated) in severe sepsis and septic shock.
Lai PS; Matteau A; Iddriss A; Hawes JC; Ranieri V; Thompson BT
Minerva Anestesiol; 2013 Jan; 79(1):33-43. PubMed ID: 23174922
[TBL] [Abstract][Full Text] [Related]
19. Drotrecogin alfa (activated) in adults with septic shock.
Ranieri VM; Thompson BT; Barie PS; Dhainaut JF; Douglas IS; Finfer S; Gårdlund B; Marshall JC; Rhodes A; Artigas A; Payen D; Tenhunen J; Al-Khalidi HR; Thompson V; Janes J; Macias WL; Vangerow B; Williams MD;
N Engl J Med; 2012 May; 366(22):2055-64. PubMed ID: 22616830
[TBL] [Abstract][Full Text] [Related]
20. Drotrecogin alfa (activated) in sepsis: initial experience with patient selection, cost, and clinical outcomes.
Higgins TL; Steingrub JS; Tereso GJ; Tidswell MA; McGee WT
J Intensive Care Med; 2005; 20(6):339-45. PubMed ID: 16280407
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
